An interventional study of Apneic oxygenation and Usual Care in Hypoxemic Acute Respiratory Failure, sponsored by University Hospital, Tours. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University Hospital, Tours · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Respiratory Insufficiency with a site in France — 20 open to participants now, 21 under way, 2 of them phase 3. Respiratory Insufficiency · France.
Among the 127 studies in Respiratory Insufficiency with a site in France, this one is the 11th largest by planned enrollment of the 78 interventional ones that give a count, is one of 7 that started in 2026, is one of 64 with no phase, reaches primary completion later than 19 of the 20 other live ones, and was the 122nd registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →20 of the 127 studies in Respiratory Insufficiency with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Departemental Vendee · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18–85
University Hospital, Brest · Sites in France
Ages 18+
University Hospital, Rouen · Sites in France
Ages 18+
GCS Ramsay Santé pour l'Enseignement et la Recherche · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 60 across 861 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 82 across the 78 interventional studies, 110 across the 47 observational. Of the 81 that completed or were terminated, 4 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 127 have an industry lead sponsor. The 10 most frequent:
University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.
University Hospital, Tours has 3 studies filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
7 of the studies in Respiratory Insufficiency with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06213168Assistance Publique - Hôpitaux de ParisImpact on Mortality of a Strategy Including Continuous Positive Airway Pressure Plus High Flow Nasal Cannula Oxygen Therapy Versus High Flow Nasal Cannula Oxygen Therapy Alone in Patients With de Novo Acute Hypoxemic Respiratory Failure: a Prospective, Randomized Controlled Trial. | 2026-12 |
| NCT06104956University Hospital, ToursWeaning Protocol for High-flow Nasal Oxygen Therapy in Intensive Care | 2027-02 |
| NCT06653933University Hospital, GrenobleStudy of Sleep Quality in the Intensive Care Unit and Association with Weaning from Invasive Ventilation in Patients with Chronic Obstructive Bronchopneumopathy. | 2027-02-01 |
| NCT07334457University Hospital, Strasbourg, FranceStudy of Platelet Population Changes Under Circulatory Support With ECMO | 2027-03 |
| NCT07522450University Hospital, RouenBenefit of Sleep Quality Monitoring by EEG in ICU | 2027-03-20 |
Add all 7 to your calendar (.ics) → With an account.
Among the 127 studies in Respiratory Insufficiency with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this clinical study is to assess whether apneic oxygenation with High-Flow Nasal Oxygen (HFNO) would decrease the incidence of severe hypoxemia compared to no apneic oxygenation during the intubation procedure (from the start of laryngoscopy to 5 minutes after successful intubation) in patients with hypoxemic acute respiratory failure.
The sponsor expects that apneic oxygenation (between the laryngoscopy and the success of intubation) with HFNO compared to no apneic oxygenation could decrease the risk of severe hypoxemia after intubation in hypoxemic critical ill patients.
Participants will be enrolled according to eligibility criteria and randomized into one of the following groups:
Experimental group : Apneic oxygenation will be used with HFNO between the laryngoscopy and the successful intubation (study intervention).
non-invasive ventilation (NIV) alone will be used for the preoxygenation and hypoventilation phase until the laryngoscopy. The nasal cannulas of HFNO will be placed on hold beneath the patient's chin (with HFNO on and set with a flow at 60-70L.min-1, FiO2 1.0) pending laryngoscopy began.
At the time of laryngoscopy: after removing the facemask of NIV, the nasal cannulas for HFNO will be placed in the patient's nares then the laryngoscopy will be performed.
Control group: The control group will receive usual care, i.e., no oxygen during the apneic phase (between the laryngoscopy and the success of the intubation procedure) During the preoxygenation and hypoventilation phase until laryngoscopy, NIV alone will be used as in the experimental group.
Endotracheal intubation is often performed in intensive care unit (ICU). Severe complications (such as severe hypoxemia, hypotension, cardiac arrest) occur up to 50%. Severe hypoxemia is more frequent in patients with hypoxemia prior to intubation or during difficult intubation and could increase the risk of cardiac arrest.
The procedure of intubation includes, in order 1) a preoxygenation phase ending with iv administration of anesthetic drugs 2) a hypoventilation phase 3) an apneic phase beginning with laryngoscopy and ending with successful intubation 4) mechanical ventilation. Optimization of this procedure is essential.
Non-invasive ventilation (NIV) is recommended for preoxygenation in hypoxemic patients and this technique can maintain ventilation during the hypoventilation phase.
Apneic oxygenation is defined as the administration of oxygen during the apneic phase. The objective is to increase the duration of apnea without desaturation. In physiological studies and in the operating room, when apneic oxygen is used with standard oxygen (up to 15L/min) or high-flow nasal oxygenation (HFNO) (up to 70L/min and FiO2 at 1.0), the apnea length without desaturation can reach several minutes.
Several meta-analyses (with high heterogeneity between studies) found that apneic oxygenation (including standard oxygen or HFNO) in emergency intubation could decrease the risk of hypoxemia. In most studies that investigated the effect of HFNO as apneic oxygenation, HFNO was also used as a preoxygenation method. Thus, the different methods of preoxygenation could affect the real effect of apneic oxygenation.
Only one single-center study evaluated apneic oxygenation with HFNO after preoxygenation by NIV. In this study the lowest SpO2 during intubation procedure was significantly higher in the apneic oxygenation group. However, in this study the mask used for NIV was applied over the nasal cannulas of HFNO, which may have resulted in less efficient preoxygenation due to leakage.
Intubation rate for HFNO failure during acute respiratory failure is about 40% in ICU patients. The question of continuing HFNO or not during the apnea phase remains open. The experts suggest continuing HFNO during intubation (conditional recommendation, moderate certainty).
We hypothesized that apneic oxygenation (between the laryngoscopy and the success of intubation) with HFNO compared to no apneic oxygenation could decrease the risk of severe hypoxemia after intubation in hypoxemic critical ill patients.
In both groups, NIV will be used during the preoxygenation and hypoventilation phases.
Procedure of intubation will be standardized according to guidelines
Preoxygenation will be performed using NIV through a facemask in both group
At the time of laryngoscopy :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Indication of orotracheal intubation for Hypoxemic acute respiratory failure defined by:
Exclusion Criteria:
\< 18 years old
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apneic oxygenation will be used with HFNO between the laryngoscopy and the successful intubation (study intervention). NIV alone will be used for the preoxygenation and hypoventilation phase until the laryngoscopy. Apneic oxygenation will be used with HFNO at the time of laryngoscopy after removing the facemask of NIV (with HFNO on and set with a flow at 60-70L.min-1, FiO2 1.0)
Procedure: Apneic oxygenation
The control group will receive usual care, i.e., no oxygen during the apneic phase (between the laryngoscopy and the success of the intubation procedure) During the preoxygenation and hypoventilation phase until laryngoscopy, NIV alone will be used as in the experimental group.
Procedure: Usual Care
* Preoxygenation will be performed using NIV for 3-5 min With nasal cannulas placed in standby beneath the patient's chin (with HFNO on and set with a flow at 60-70L.min-1, FiO2 1.0) * Rapide sequence induction * Hypoventilation phase will be continue for 1 min using NIV * At the time of laryngoscopy : After removing the facemask, the nasal cannulas of HFNO will be placed in the patient's nares then the laryngoscopy will be performed. \* Use of capnography to confirm the success of procedure
* Preoxygenation will be performed using NIV for 3-5 min without HFNO * Rapide sequence induction * Hypoventilation phase will be continue using NIV for 1min * At the time of laryngoscopy : After removing the facemask, laryngoscopy will be performed without oxygen. \* Use of capnography to confirm the success of procedure
Incidence of severe hypoxemia
The incidence of severe hypoxemia defined as the occurrence of at least one episode of oxygen saturation measured by pulse oximetry (SpO2) \< 80%
Time frame: from the start of laryngoscopy to 5 minutes after successful intubation
Incidence of prolonged severe hypoxemia
The incidence of prolonged severe hypoxemia defined by an SpO2 \< 80% for more than 24 seconds
Time frame: from the start of laryngoscopy to 5 minutes after successful intubation
The highest and lowest SpO2 values during the procedure
The highest and lowest SpO2 values during the procedure
Time frame: from the start of laryngoscopy to 5 minutes after successful intubation
The occurrence of each immediate severe complications
The occurrence of each immediate severe complications including cardiovascular instability (systolic arterial blood pressure \<65 mmHg at least once, new or increase need of vasopressors or fluid bolus \>15 mL/kg), cardiac arrest, new onset cardiac arrhythmia (atrial fibrillation, ventricular tachycardia, bradycardia \<30beats per minute).
Time frame: from the start of laryngoscopy to 5 minutes after successful intubation
The occurrence of each other adverse events
The occurrence of each other adverse events: difficult intubation (defined as a procedure requiring more than 2 laryngoscopy attempts before success), operator-reported aspiration between induction and intubation, dental injury, esophageal intubation, pneumothorax visualized on the follow-up chest X-ray as part of the patient's routine care.
Time frame: from the start of laryngoscopy to 5 minutes after successful intubation; At Day 28
Duration of laryngoscopy
The duration of laryngoscopy will be compared in both group
Time frame: From the 1st attempt to the successful intubation
Number of laryngoscopies
The number of laryngoscopies will be compared in both group
Time frame: from the 1st attempt to the successful intubation
Day-28 mortality
Time frame: at Day 28
Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.
Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 36 months is above that.
Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Oct 2025 → Mar 2026, primary completion Oct 2028 → Mar 2029 and completion Nov 2028 → Apr 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.